Sarah Razzak Chaudhary1, Biruh T Workeneh2, Maria E Montez-Rath3, Andrew R Zolopa4, Paul E Klotman2, Wolfgang C Winkelmayer5. 1. Department of Medicine, Santa Clara Medical Center, Santa Clara, CA, USA Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA. 2. Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA. 4. Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA ViiV Healthcare, Inc., Brentford, Middlesex, UK. 5. Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: Little is known about the trends in the incidence and outcomes of patients with end-stage renal disease (ESRD) attributed to human immunodeficiency virus-associated nephropathy (HIVAN). We sought to define relative incidence among ESRD patients, changes in mortality among patients with ESRD attributed to HIVAN, as well as changes in the excess mortality experienced by patients with ESRD attributed to HIVAN compared with otherwise similar ESRD patients with non-HIVAN causes. METHODS: We used the US Renal Data System to identify all individuals with reported HIVAN who initiated treatment for ESRD between 1989 and 2011. We plotted their counts and proportions among all incident ESRD patients and tabulated their characteristics across years. We then compared mortality within the HIVAN group across years using Cox regression. In addition, we studied the trends in relative mortality of HIVAN patients versus those with ESRD not reported as HIVAN. RESULTS: Overall, 14 719 individuals with HIVAN-ESRD were recorded, with significant reductions in recent years (893 in 2006; 525 in 2011). Compared with patients initiating dialysis between 1989 and 1992, mortality declined by 40% (HR = 0.60; 95% CI, 0.55-0.65) and 64% (HR = 0.36; 95% CI, 0.32-0.40) for patients initiating dialysis in 1999/2000 and 2009-11, respectively. The adjusted excess mortality of HIVAN-ESRD patients versus incident ESRD patients from other causes was >5-fold in 1989-92 (HR = 5.21; 95% CI, 4.84-5.60); this excess mortality has subsequently declined but remained at almost 3-fold in recent years (e.g. HR = 2.58; 95% CI, 2.37-2.80, 2009-11 incidence cohort). CONCLUSIONS: Concurrent with the increasing availability of highly active antiretroviral therapy (HAART), both the incidence of ESRD due to HIVAN and the mortality of such patients have decreased substantially. However, HIVAN patients reaching ESRD continue to experience substantial excess mortality compared with other ESRD patients even in the current era of modern HAART.
BACKGROUND: Little is known about the trends in the incidence and outcomes of patients with end-stage renal disease (ESRD) attributed to human immunodeficiency virus-associated nephropathy (HIVAN). We sought to define relative incidence among ESRDpatients, changes in mortality among patients with ESRD attributed to HIVAN, as well as changes in the excess mortality experienced by patients with ESRD attributed to HIVAN compared with otherwise similar ESRDpatients with non-HIVAN causes. METHODS: We used the US Renal Data System to identify all individuals with reported HIVAN who initiated treatment for ESRD between 1989 and 2011. We plotted their counts and proportions among all incident ESRDpatients and tabulated their characteristics across years. We then compared mortality within the HIVAN group across years using Cox regression. In addition, we studied the trends in relative mortality of HIVAN patients versus those with ESRD not reported as HIVAN. RESULTS: Overall, 14 719 individuals with HIVAN-ESRD were recorded, with significant reductions in recent years (893 in 2006; 525 in 2011). Compared with patients initiating dialysis between 1989 and 1992, mortality declined by 40% (HR = 0.60; 95% CI, 0.55-0.65) and 64% (HR = 0.36; 95% CI, 0.32-0.40) for patients initiating dialysis in 1999/2000 and 2009-11, respectively. The adjusted excess mortality of HIVAN-ESRDpatients versus incident ESRDpatients from other causes was >5-fold in 1989-92 (HR = 5.21; 95% CI, 4.84-5.60); this excess mortality has subsequently declined but remained at almost 3-fold in recent years (e.g. HR = 2.58; 95% CI, 2.37-2.80, 2009-11 incidence cohort). CONCLUSIONS: Concurrent with the increasing availability of highly active antiretroviral therapy (HAART), both the incidence of ESRD due to HIVAN and the mortality of such patients have decreased substantially. However, HIVAN patients reaching ESRD continue to experience substantial excess mortality compared with other ESRDpatients even in the current era of modern HAART.
Authors: Wendy S Post; Matthew Budoff; Lawrence Kingsley; Frank J Palella; Mallory D Witt; Xiuhong Li; Richard T George; Todd T Brown; Lisa P Jacobson Journal: Ann Intern Med Date: 2014-04-01 Impact factor: 25.391
Authors: Tahira P Alves; Todd Hulgan; Pingsheng Wu; Timothy R Sterling; Samuel E Stinnette; Peter F Rebeiro; Andrew J Vincz; Marino Bruce; T Alp Ikizler Journal: Clin J Am Soc Nephrol Date: 2010-09-28 Impact factor: 8.237
Authors: Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel Journal: N Engl J Med Date: 2013-11-09 Impact factor: 91.245
Authors: Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Charles Herzog; Areef Ishani; Kirsten Johansen; Bertram Kasiske; Nancy Kutner; Jiannong Liu; Wendy St Peter; Shu Ding; Haifeng Guo; Allyson Kats; Kenneth Lamb; Shuling Li; Suying Li; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Bryn Thompson; Eric Weinhandl; Hui Xiong; Akeem Yusuf; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frank Daniels; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2013-01 Impact factor: 8.860
Authors: A Ganesan; E M Krantz; K Huppler Hullsiek; M S Riddle; A C Weintrob; T Lalani; J F Okulicz; M Landrum; B Agan; T J Whitman; M J Ross; N F Crum-Cianflone Journal: HIV Med Date: 2012-07-19 Impact factor: 3.180
Authors: J Bradley Layton; Susan L Hogan; Caroline E Jennette; Barbara Kenderes; Jenna Krisher; J Charles Jennette; William M McClellan Journal: Clin J Am Soc Nephrol Date: 2010-08-05 Impact factor: 8.237
Authors: Andy I Choi; Rudolph A Rodriguez; Peter Bacchetti; Paul A Volberding; Diane Havlir; Daniel Bertenthal; Alan Bostrom; Ann M O'Hare Journal: Clin Infect Dis Date: 2007-12-15 Impact factor: 9.079
Authors: Jayme E Locke; Shikha Mehta; Deirdre Sawinski; Sally Gustafson; Brittany A Shelton; Rhiannon D Reed; Paul MacLennan; Charlotte Bolch; Christine Durand; Allan Massie; Roslyn B Mannon; Robert Gaston; Michael Saag; Turner Overton; Dorry L Segev Journal: Clin J Am Soc Nephrol Date: 2017-02-23 Impact factor: 8.237
Authors: Anqun Chen; Jin Xu; Han Lai; Vivette D D'Agati; Tian-Jun Guan; Shawn Badal; John Liles; John C He; Kyung Lee Journal: Nephrol Dial Transplant Date: 2021-02-20 Impact factor: 5.992
Authors: Brian J Boyarsky; Mary Grace Bowring; Ashton A Shaffer; Dorry L Segev; Christine M Durand Journal: Curr Opin Organ Transplant Date: 2019-08 Impact factor: 2.640